Lyme Disease Information for Health Professionals

On this page:
Required Disease Reporting
Clinical Features
Guidelines
Presentations
More from other web sites

Lyme disease

  • The pathognomonic erythema migrans (EM) rash is present in the majority (but not all) cases of Lyme disease. It is not always “bulls-eye” in appearance but does expand in size over time. If a patient has an EM highly suggestive of Lyme disease and recent symptom onset (<2-3 weeks), B. burgdorferi antibody tests are not recommended because of low sensitivity at this stage of infection.
  • Seroconversion to IgG antibodies on Western blot is expected for patients with symptoms lasting > 1 month. For patients who have had signs and symptoms for >1 month or who do not have an EM rash, diagnosis should be based on laboratory tests in addition to symptomatology.
  • Long-term or repeated antibiotics for the treatment of “chronic” Lyme disease is not necessary, safe, or recommended. Evidence does not demonstrate persistence of viable B. burgdorferi after treatment with the correct antibiotic for the indicated treatment duration (2-4 weeks). Persistent symptoms following proper treatment may be due to lingering inflammatory processes, an unrecognized tick-borne coinfection, or an unrelated process.
Full May 6, 2011: Tick-borne Disease Health Alert

 

Required Disease Reporting

  • Reporting Lyme Disease
    Minnesota Rules Governing Communicable Diseases require health care providers to report cases of Lyme disease (Borrelia burgdorferi) to the Minnesota Department of Health (MDH) within 1 working day.

    MDH staff also are available to provide clinical consultation regarding diagnosis and treatment of Lyme disease and other tick-borne diseases. Call 651-201-5414 for a clinical consultation.

Clinical Features

Guidelines

Presentations

More from other web sites:

Updated Tuesday, July 01, 2014 at 01:22PM